The extracellular domain of p185c-neu induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo

DNA and Cell Biology

Volumn 25, Issue 9, 2006, Pages 530-540

  Yoneda, Tsutomu ^a   Kumagai, Toru ^a   Nagatomo, Izumi ^a   Furukawa, Mitsugi ^a   Yamane, Hiroyuki ^a   Hoshino, Shigenori ^a   Mori, Masahide ^a   Takeda, Yoshito ^a   Horai, Takeshi ^b   Nishida, Sumiyuki ^a   Watanabe, Dai ^a   Kijima, Takashi ^a   Yoshida, Mitsuhiro ^a   Osaki, Tadashi ^a   Tachibana, Isao ^a   Greene, Mark I ^c   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P185; PROTEIN P185C NEU; PROTEIN P21; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL DENSITY; CELL TRANSFORMATION; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHEMISTRY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; MESOTHELIOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; PROTO ONCOGENE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 33750631870     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.530     Document Type: Article

References (62)

1. AIGNER, A., JUHL, H., MALERCZYK, C., TKYBUSCH, A., BENZ, C.C., and CZUBAYKO, F. (2001). Expression of a truncated 100kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 20, 2101-2111.
2. AZIOS, N.G., ROMERO, F.J., DENTON, M.C., DOHERTY, J.K., and CLINTON, G.M. (2001). Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 20, 5199-5209.
3. BARGMANN, C.I., HUNG, M.C., and WEINBERG, R.A. (1986). The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226-230.
4. BEER, T.W., SHEPHERD, P., and PULLINGER, N.C. (2001). p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 38, 535-541.
5. BEREZOV, A., CHEN, J., LIU, Q., ZHANG, H.T., GREENE, M.I., and MURALI, R. (2002). Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 277, 28330-28339.
6. BERMUDEZ, E., EVERITT, J., and WALKER, C. (1990). Expression of growth factor and growth factor receptor RNA in rat pleural mesothelial cells in culture. Exp. Cell Res. 190, 91-98.
7. BRUGAROLAS, J., BRONSON, R.T., and JACKS, T. (1998). p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J. Cell Biol. 141, 503-514.
8. CHELLAPPAN, S.P., HIEBERT, S., MUDRYJ, M., HOROWITZ, J.M., and NEVINS, J.R. (1991). The E2F transcription factor is a cellular target for the RB protein. Cell 65, 1053-1061.
9. CRYNS, V.L., THOR, A., XU, H.J., HU, S.X., WIERMAN, M.E., VICKERY, A.L., JR., BENEDICT, W.F., and ARNOLD, A. (1994). Loss of The retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N. Engl. J. Med. 330, 757-761.
10. DEB, T.B., SU, L., WONG, L., BONVINI, E., WELLS, A., DAVID, M., and JOHNSON, G.R. (2001). EGF receptor kinase-independent signaling by EGF. J. Biol. Chem. 276, 15554-15560.
11. DE PANGHER, M.V., BROLLO, A., FRANCESCHI, S., DE MATTHAEIS, M., TALAMINI, R., and BLANCHI, C. (1993). Prognostic factors of malignant mesothelioma of the pleura. Cancer 72, 410-417.
12. DESTRO, A, CERESOLI, G.L., FALLENI, M., ZUCALI, P.A., MORENGHI, E., BIANCHI, P., PELLEGRINI, C., CORDANI, N., VAIRA, V., et al. (2006). EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51, 207-215.
13. DOHERTY, J.K., BOND, C., JARDIM, A., ADELMAN, J.P., and CLINTON, G.M. (1999). The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. USA 96, 10869-10874.
14. FLICKINGER, T.W., MAIHLE, N.J., and KUNG, H.J. (1992), An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol. Cell Biol. 12, 883-893.
15. FRIEND, S.H., BERNARDS, R., ROGELJ, S., WEINBERG, R.A., RAPAPORT, J.M., ALBERT, D.M., and DRYJA, T.P. (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643-646.
16. GAITS, F., LI, R.Y., RAGAB, A., RAGAB-THOMAS, J.M., and CHAP, H. (1995). Increase in receptor-like protein tyrosine phosphatase activity and expression level on density-dependent growth arrest of endothelial cells. Biochem. J. 311, 97-103.
17. CIP1/WAF1 in the antiproliferative effect of ZD1839 ("Iressa"), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J. Cell Physiol. 195, 139-150.
18. GRAUS-PORTA, D., BEERLI, R.R., DALY, J.M., and HYNES, N.E. (1997). ErbB2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655.
19. HARPER, J.W., ADAMI, G.R., WEI, N., KEYOMARSI, K., and ELLEDGE, S.J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
20. HELDIN, C.-H. (1995). Dimerization of cell surface receptors in signal transduction. Cell 80, 213-223.
21. HUNG, M.C., SCHECHTER, A.L., CHEVRAY, P.Y., STERN, D.F., and WEINBERG, R.A. (1986). Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles. Proc. Natl. Acad. Sci. USA 83, 261-264.
22. IWAMOTO, R., HANDA, K., and MEKADA, E. (1999). Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J. Biol. Chem. 274, 25906-25912.
23. JANNE, P.A., TAFFARO, M.L., SALGIA, R., and JOHNSON, B.E. (2002). Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 62, 5242-5247.
24. JARDINES, L., WEISS, M., FOWBLE, B., and GREENE, M. (1993). neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61, 268-282.
25. JAWHARI, A.U., FARTHING, M.J.G., PIGNATELLI, M. (1999). The E-cadherin/epidermal growth factor receptor interaction: A hypothesis of reciprocal and reversible control of intercellular adhesion and cell proliferation. J. Pathol. 187, 155-157.
26. JHABVALA-ROMERO, F., EVANS, A., GUO, S., DENTON, M., and CLINTON, G.M. (2003). Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 22, 8178-8186.
27. JORISSEN, R.N., WALKER, F., POULIOT, N., GARRETT, T.P.J., WARD, C.W., and BURGESS, A.W. (2003). Epidermal growth factor receptor: Mechanisms of activation and signaling. Exp. Cell Res. 284, 31-53.
28. KAWAMOTO, T., MENDELSOHN, J., LE, A., SATO, G.H., LAZAR, C.S., and GILL, G.N. (1984). Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J. Biol. Chem. 259, 7761-7766.
29. KNUDSEN, E.S., and WANG, J.Y.J. (1997). Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell Biol. 17, 5771-5783.
30. KOKAI, Y., MYERS, J.N., WADA, T., BROWN, V.I. LEVEA, C.M., DAVIS, J.G., DOBASHI, K., and GREENE, M.I. (1989). Synergistic interaction of p 185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58, 287-292.
31. KRAUS, M.H., ISSING, W., MIKI, T., POPESCU, N.C., and AARONSON, S.A. (1989). Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA. 86, 9193-9197.
32. KUMAGAI, T., TANIO, Y., OSAKI, T., HOSOE, S., TACHIBANA, I., UENO, K., KIJIMA, T., HORAI, T., and KISHIMOTO, T. (1996). Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res. 56, 354-358.
33. neu extracellular sub-domains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling. Proc. Natl. Acad. Sci. USA 98, 5526-5531.
34. KUMAGAI, T., KATSUMATA, M., HASEGAWA, A., FURUUCHI, K., FUNAKOSHI, T., KAWASE, I., and GREENE, M.I. (2003). Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and ligand-induced transactivation. Proc. Natl. Acad. Sci. USA 100, 9220-9225.
35. LEE, H., AKITA, R.W., SLIWKOWSKI, M.X., and MAIHLE, N.J. (2001). A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. 61, 4467-4473.
36. MOSSMAN, B.T., and GRUENERT, D.C. (2002). SV40, growth factors, and mesothelioma: Another piece of the puzzle. Am. J. Respir. Cell Mol. Biol. 26, 167-170.
37. NAGATOMO, I., KUMAGAI, T., YAMADORI, T., FURUKAWA, M., TAKAHASHI. R., YONEDA, T., OGATA, Y., SAITO, Y., INOUE, K., YANO, Y., et al. (2006). The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. DNA Cell Biol. 25, 246-251.
38. NAKAYAMA, K., and NAKAYAMA, K. (1998). Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development. Bioessays 20, 1020-1029.
39. NICHOLSON, R.I., GEE, J.M., and HARPER, M.E. (2001). EGFR and cancer prognosis. Eur. J. Cancer 37, S9-S15.
40. O'BYRNE, K.J., EDWARDS, J.G., and WALLER, D.A. (2004). Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 455, 545-548.
41. OLAYIOYE, M.A., NEVE, R.M., LANE, H.A., and HYNES, N.E. (2000). The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167.
42. HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18, 194-198.
43. PINKAS-KRAMARSKI, R., SOUSSAN, L., WATERMAN, H., LEVKOWITZ, G., ALROY, I., KLAPPER, L., LAVI, S., SEGER, R., RATZKIN, B.J., SELA, M., et al. (1996). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452-2467.
44. PLOWMAN, G.D., WHITNEY, G.S., NEUBAUER, M.G., GREEN, J.M., MCDONALD, V.L., TODARO, G.J., and SHOYAB, M. (1990). Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl. Acad. Sci. USA 87, 4905-4909.
45. QIAN, X., DOUGALL, W.C., HELLMAN, M.E., and GREENE, M.I. (1994). Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene 9, 1507-1514.
46. QIAN, X., O'ROURKE, D.M., ZHAO, H., and GREENE, M.I. (1996). Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene 13, 2149-2157.
47. QIAN, X., KARPOVA, T., SHEPPARD, A.M., MCNALLY, J., and LOWY, D.R. (2004). E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 23, 1739-1784.
48. RAMAEL, M., SEGERS, K., BUYSSE, C., VAN DEN BOSSCHE, J., and VAN MARCK, E. (1991). Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch. A. Oathol. Anat. Histopathol. 419, 171-175.
49. SHERR, C.J., and MCCORMICK, F. (2002). The RB and p53 pathways in cancer. Cancer Cell 2, 103-112.
50. SHERR, C.J., and ROBERTS, J.M. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163.
51. SHERR, C.J., and ROBERTS, J.M. (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512.
52. SHIOZAKI, H., KADOWAKI, T., DOKI, Y., INOUE, M., TAMURA, S., OKA, H., IWAZAWA, T., MATSUI, S., SHIMAYA, K., TAKEICHI, M., et al. (1995). Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br. J. Cancer 71, 250-258.
53. STANBRIDGE, E.J., and WILKINSON, J. (1978). Analysis of malignancy in human cells: Malignant and transformed phenotypes are un-der separate genetic control. Proc. Natl. Acad. Sci. USA 75, 1466-1469.
54. TAKAHASHI, K., and SUZUKI, K. (1996). Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp. Cell Res. 226, 214-222.
55. THIRKETTLE, I., HARVEY, P., HASLETON, P.S., BALL, R.Y., and WARM, R.M. (2000). Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 36, 522-528.
56. TOMEK, S., EMRI, S., KREJCY, K., and MANEGOLD, C. (2003). Chemotherapy for malignant pleural mesothelioma: Past results and recent developments. Br. J. Cancer 88, 167-174.
57. TOYOSHIMA, H., and HUNTER, T. (1994). p27, a novel inhibitor of Gl cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67-74.
58. ULLRICH, A., COUSSENS, L., HAYFLICK, J.S. DULL, T.J., GRAY, A., TAM, A.W., LEE, J., YARDEN, Y., LIBERMANN, T.A., SCHLESSINGER, J., et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425.
59. WADA, T., QIAN, X.L., and GREENE, M.I. (1990). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61, 1339-1347.
60. WRIGHT, C., ANGUS, B., NICHOLSON, S., SAINSBURY, J.R., CAIRNS, J., GULLICK, W.J., KELLY, P., HARRIS, A.L., and HORNE, C.H. (1989). Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res. 49, 2087-2090.
61. XU, H.J., HU, S.X., CAGLE, P.T., MOORE, G.E., and BENEDICT, W.F. (1991). Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. 51, 2735-2739.
62. YAMAMOTO, T., IKAWA, S., AKIYAMA, T., SEMBA, K., NOMURA, N. MIYAJIMA, N., SAITO, T., and TOYOSHIMA, K. (1986). Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319, 230-234.